Download MendeleyDarobactins Exhibiting Superior Antibiotic Activity by Cryo-EM Structure Guided Biosynthetic Engineering.
Seyfert, C.E., Porten, C., Yuan, B., Deckarm, S., Panter, F., Bader, C.D., Coetzee, J., Deschner, F., Tehrani, K.H.M.E., Higgins, P.G., Seifert, H., Marlovits, T.C., Herrmann, J., Muller, R.(2023) Angew Chem Int Ed Engl 62: e202214094-e202214094
- PubMed: 36308277
- DOI: https://doi.org/10.1002/anie.202214094
- Primary Citation of Related Structures:
8ADG, 8ADI - PubMed Abstract:
Over recent decades, the pipeline of antibiotics acting against Gram-negative bacteria is running dry, as most discovered candidate antibiotics suffer from insufficient potency, pharmacokinetic properties, or toxicity. The darobactins, a promising new small peptide class of drug candidates, bind to novel antibiotic target BamA, an outer membrane protein. Previously, we reported that biosynthetic engineering in a heterologous host generated novel darobactins with enhanced antibacterial activity. Here we utilize an optimized purification method and present cryo-EM structures of the Bam complex with darobactin 9 (D9), which served as a blueprint for the biotechnological generation of twenty new darobactins including halogenated analogs. The newly engineered darobactin 22 binds more tightly to BamA and outperforms the favorable activity profile of D9 against clinically relevant pathogens such as carbapenem-resistant Acinetobacter baumannii up to 32-fold, without observing toxic effects.
Organizational Affiliation:
Microbial Natural Products, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI), Department of Pharmacy at, Saarland University Campus Building E8.1, 66123 Saarbrücken (Germany).
